<DOC>
	<DOCNO>NCT01547104</DOCNO>
	<brief_summary>The goal mechanistic study investigate effect Linagliptin comparison Glimepiride add therapy several parameter characterize postprandial metabolism oxidative stress type 2 diabetic patient stable control metformin .</brief_summary>
	<brief_title>Effect Linagliptin Comparison With Glimepiride Add Metformin Postprandial Beta Cell Function , Postprandial Metabolism Oxidative Stress Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The goal mechanistic study investigate effect Linagliptin comparison Glimepiride add therapy several parameter characterize postprandial metabolism oxidative stress type 2 diabetic patient stable control metformin . This mechanistic phase IV study prospective , comparative , open , randomize , two arm exploratory design . Overall 40 Patients randomized two treatment arm receive Metformin maximally tolerate dose . In addition treatment group receive either individually titrate dose Glimepiride 5mg daily Linagliptin . Subsequent standardize meal , several parameter reflect beta cell function , metabolism oxidative stress evaluate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>1 . Diabetes mellitus type 2 2 . HbA1c &gt; 6.5 % ≤ 8.5 % 3 . HbA1c &gt; 7.0 % ≤ 8.5 % patient significant cardiovascular history 4 . Treatment metformin maximum tolerate dose 5 . Age 45 75 year ( inclusively ) 6 . Patient consent his/her family physician/diabetologist inform trial participation . 1 . Pretreatment PPAR gamma agonist within last three month 2 . History type 1 diabetes 3 . Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) 4 . Acute infection 5 . Medical history hypersensitivity study drug drug similar chemical structure 6 . History severe multiple allergy 7 . Treatment investigational drug within 3 month trial entry . 8 . Progressive fatal disease 9 . History drug alcohol abuse past 2 year 10 . State kidney transplantation 11 . Serum potassium &gt; 5.5 mmol/L 12 . Pregnancy breast feed 13 . Sexually active woman childbearing age practice highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , sexual abstinence vasectomize partner . 14 . Acute myocardial infarction , open heart surgery cerebral event ( stroke/TIA ) within previous 30 day 15 . Any elective surgery study participation 16 . Have one unexplained episode severe hypoglycemia ( define require assistance another person due disable hypoglycemia ) within 6 month prior screen visit 17 . History pancreatitis 18 . History dehydration , precoma diabeticum diabetic ketoacidosis 19 . Acute schedule investigation iodine contain radiopaque material 20 . Uncontrolled unstable angina pectoris 21 . History pericarditis , myocarditis , endocarditis 22 . Recent pulmonary embolism 23 . Hemodynamic relevant aortic stenosis 24 . Aortic aneurysm 25 . Regular use NSAID 's ( acute use NSAID within 48 hour V2 , V4 , V5 ) 26 . Lack compliance similar reason , accord investigator , preclude satisfactory participation study 27 . History respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( Creatinine &gt; 1.1 mg/dl woman &gt; 1.5 mg/dl men ) , neurological , psychiatric and/or hematological disease judge investigator 28 . Lactose intolerance 29 . Intake Coumarin coumarin derive compound phenprocoumon ( Marcumar ) warfarin ( Coumadin , Warfant )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>